Multiple Sclerosis Medication Review Articles

Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS) that mainly affects young adults. The exact mechanism and pathogenesis of MS is still unknown, but there have been useful treatments with different rates of effectiveness. Most of these therapies are divided into first line, second line and third line, impact on the immune system and immune cells. These drugs are approved to be useful in MS, but like any other treatment, side effects (AEs) are associated with these drugs. In this review, we continue to investigate the mechanisms of action and the AEs of MS drugs. Doctors need to be aware of these AEs and complications to choose the best medication for each patient. Multiple sclerosis (MS) is an autoimmune inflammatory of the central nervous system (CNS), the etiology of which is unknown and the incidence of which is higher in women [1,2]. The roles of the immune system and immune cells can be considered an important basis for this disease [3] but certain environmental factors and hormones have also been recognized to influence MS [4,5]. Based on the immune base of MS, certain treatments and drugs have been discovered with different efficacies and indications for MS that mainly suppress the immune system so that the myelin sheath can be saved or the patient can undergo treatment. remission. Unfortunately, there are some side effects (AEs) associated with these drugs that can be considered mild or even serious. Previously, in the first part of the review article, we had carried out a survey on the mechanisms of action and certain AEs of certain drugs against MS and we are continuing here our investigation on these drugs: glatiramer acetate, alemtuzumab, dimethyl fumarate, teriflunomide, laquinimod, rituximab, daclizumab and Cladribine. This systematic review article is done by searching the PubMed and Goggle Scholar search engine and by examining different clinical trials and an old review article on different MS drugs. In the end, we summarize these AEs